Last reviewed · How we verify
NCT05127798
RWE of 1st Line Treatment in Adults With AML From 18 to 70 Years Old.
trial testing Evaluation of first line treatment with intensive treatment outcome in adult patients with AML. in Acute Myeloid Leukemia, Adult in 50 participants. Status unknown.
1 March 2024
Quick facts
| Lead sponsor | Grupo Argentino de Tratamiento de la Leucemia Aguda |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 1 March 2021 |
| Primary completion | 1 March 2024 |
| Estimated completion | 1 December 2024 |
| Sites | 2 locations across Argentina |
Drugs / interventions tested
- Evaluation of first line treatment with intensive treatment outcome in adult patients with AML.
Conditions studied
- Acute Myeloid Leukemia, Adult — all drugs for Acute Myeloid Leukemia, Adult →
Sponsor
Grupo Argentino de Tratamiento de la Leucemia Aguda — full company profile →
Who can join
Adults 18 to 70, any sex, with Acute Myeloid Leukemia, Adult. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multicenter, observational real world clinical trial with prospective follow up that will evaluate the treatment outcome of Acute Myeloid Leukemia (AML) patients in the first line with intensive chemotherapy based regimens in Argentina.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05127798
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Myeloid Leukemia, Adult
Currently open trials in the same condition.
- NCT06652438 — Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML · Phase 3 · recruiting
- NCT06532552 — Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Ne · Phase 2 · recruiting
- NCT06199557 — A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients · Phase 1, PHASE2 · recruiting
- NCT05703126 — Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML · NA · recruiting
- NCT05133882 — A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML · Phase 1, PHASE2 · recruiting
Other Grupo Argentino de Tratamiento de la Leucemia Aguda trials
Trials by the same sponsor.
- NCT05360758 — Ibrutinib Adapted to Response in Patients With CLL · unknown
- NCT04776265 — RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT · unknown
- NCT05078840 — PET Adapted Treatment of Patients With Limited Stage DLBCL and no Risk Factors · unknown
- NCT05127148 — RWE of Pediatric-like Protocol for AYA Patients With Ph-negative ALL · recruiting
- NCT06211452 — Comparison of Consolidation Strategies for Pediatric Patients With Acute Myeloid Leukemia · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05127798 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Grupo Argentino de Tratamiento de la Leucemia Aguda
- Last refreshed: 19 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05127798.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing